Compare Mesoblast Limited (MESO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Riot Platforms Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Riot Platforms Inc trades at $20.49 (market cap $7.53B). The key difference: Riot Platforms Inc is far larger — about 3.5× Mesoblast Limited's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | RIOT | |
|---|---|---|
Market Cap | $2.17B | $7.53B |
Sector | Technology | Technology |
52-Week High | $20.96 | $28.67 |
52-Week Low | $12.88 | $11.03 |
Enterprise Value | $2.17B | $8.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
RIOT trades at $19.90, up 8.98% today but facing bearish technical signals with the stock trading below key resistance levels. The company reported a net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Analyst consensus remains overwhelmingly bullish with 94% buy ratings and a $27.86 price target, representing 40% upside potential from current levels.
While Wall Street maintains strong buy recommendations, RIOT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's investment case hinges on successful execution of the company's strategic pivot toward high-performance computing and data center expansion, though operational losses and competitive pressures present substantial risks to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
